Nov 10. 2022

KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting

Nov 1. 2022

KaliVir Appoints Industry Veteran Adina Pelusio as Senior Vice President of Clinical Operations to Lead Clinical Development Pipeline

Oct 24. 2022

KaliVir Immunotherapeutics to Present at 14th International Oncolytic Virotherapy Conference (IOVC)

Oct 5. 2022

KaliVir Immunotherapeutics to Present Data on its Novel Pre-Clinical Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) Annual Meeting

May 23. 2022

KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses

Mar 16. 2022

KaliVir Immunotherapeutics Closes Series A Financing

Nov 4. 2021

KaliVir Immunotherapeutics Strengthens Intellectual Property Position Through Issuance of Two U.S. Patents.

December 7. 2020

KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus.

2020

How Stephen Thorne and Helena Chaye are blending their talents to create Breakthrough cancer fighting therapies

June 17. 2021

KaliVir Immunotherapeutics appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors